Teva outlines strategy plans for marketing in India
A series of local collaboration and partnership agreements for the development and supply of a range of products to India is planned by the Israeli drug major Teva Pharmaceutical Holdings. These will be initiated with the company's integration plans with IVAX Corp, the $7.6 billion acquisition of which Teva has recently concluded (Marketletters passim).
This means that Teva could partner with India's Cipla, since the firm already has a pact with IVAX for a range of products for marketing in the USA.
Aharon Yaari, chief executive of the active pharmaceutical ingredients division of Teva, who was visiting India to attend the opening of the company's new center for API and R&D under Regent Drug, said in an interview that "Teva's new strategy for India is to grow through collaboration and partnership rather than via acquisitions. Besides proposed alliances in the pharma sector, Teva is also holding talks with some of the Indian biotech majors for strategic alliances."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze